Skip to main content
Fig. 9 | Journal of Neuroinflammation

Fig. 9

From: Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis

Fig. 9

SUR1 is upregulated in demyelinating white matter and cortical lesions in MS patients. a, b Immunolabeling for SUR1 in control (CTR) white matter (WM) (a, left) and in demyelinating active (a, middle) and chronic active (a, right) WM lesions, shown at low (a) and high (b) magnification. c Immunolabeling for SUR1 in control (CTR) cortex (CTX) (c, left) and in demyelinating cortical lesion (c, right); asterisk, bottom of a sulcus; scale bars 250 μm (a, c) and 50 μm (b). d Semi-quantitative assessment of SUR1 immunolabeling in different types of demyelinating lesions; n = 4–6 lesions/type; note that CTR WM exhibited no specific labeling for SUR1; **P < 0.01, ***P < 0.001 with respect to respective controls (CTR)

Back to article page